Polly A. Niravath, MD

Assistant Professor of Clinical Medicine in Oncology, Institute for Academic Medicine
Houston Methodist
Weill Cornell Medical College


Challenges of measuring accurate estradiol levels in aromatase inhibitor-treated postmenopausal breast cancer patients on vaginal estrogen therapy
Niravath, P, Bhat, R, Al-Ameri, M, AlRawi, A, Foreman, C & Trivedi, MV 2017, Pharmacology Research and Perspectives, vol 5, no. 4, e00330. DOI: 10.1002/prp2.330

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Ma, CX, Bose, R, Gao, F, Freedman, RA, Telli, ML, Kimmick, G, Winer, EP, Naughton, M, Goetz, MP, Russell, C, Tripathy, D, Cobleigh, M, Forero, A, Pluard, TJ, Anders, C, Niravath, PA, Thomas, S, Anderson, J, Bumb, C, Banks, KC, Lanman, RB, Bryce, R, Lalani, AS, Pfeifer, JD, Hayes, DF, Pegram, M, Blackwell, K, Bedard, PL, Al-Kateb, H & Ellis, MJC 2017, Clinical Cancer Research. DOI: 10.1158/1078-0432.CCR-17-0900

Retrospective review of genomic testing in breast cancer: Does it improve outcome?
Gastelum, GM, Iqbal, C, Hilsenbeck, SG, Rimawi, MF & Niravath, P 2017, Breast Cancer Research and Treatment, vol 163, no. 1, pp. 191-195. DOI: 10.1007/s10549-017-4154-3

Retrospective review of genomic testing in breast cancer: Does it improve outcome?
Gastelum, GM, Iqbal, C, Hilsenbeck, SG, Rimawi, MF & Niravath, P 2017, Breast Cancer Research and Treatment, vol 163, no. 1, pp. 191-195. DOI: 10.1007/s10549-017-4154-3

Effect of a scalp cooling device on alopecia inwomen undergoing chemotherapy for breast cancer: The SCALP randomized clinical trial
Nangia, J, Wang, T, Osborne, C, Niravath, P, Otte, K, Papish, S, Holmes, F, Abraham, J, Lacouture, M, Courtright, J, Paxman, R, Rude, M, Hilsenbeck, S, Osborne, K & Rimawi, M 2017, JAMA - Journal of the American Medical Association, vol 317, no. 6, pp. 596-605. DOI: 10.1001/jama.2016.20939

The role of genetic testing in the selection of therapy for breast cancer a review
Niravath, P, Cakar, B & Ellis, M 2017, JAMA Oncology, vol 3, no. 2, pp. 262-268. DOI: 10.1001/jamaoncol.2016.2719

Prognostic Factors, Treatment, and Outcomes in Early Stage, Invasive Papillary Breast Cancer: A SEER Investigation of Less Aggressive Treatment in a Favorable Histology
Fakhreddine, MH, Haque, W, Ahmed, A, Schwartz, MR, Farach, AM, Paulino, AC, Bonefas, E, Miltenburg, D, Niravath, P, Butler, BB & Teh, BS 2016, American Journal of Clinical Oncology: Cancer Clinical Trials. DOI: 10.1097/COC.0000000000000335

Aromatase Inhibitor-Associated Arthralgia: How Big Is the Problem and What Can Be Done?
Niravath, P 2016, Current Breast Cancer Reports, vol 8, no. 3, pp. 135-138. DOI: 10.1007/s12609-016-0217-4

Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy
Sulaica, E, Han, T, Wang, W, Bhat, R, Trivedi, MV & Niravath, P 2016, Breast Cancer Research and Treatment, vol 157, no. 2, pp. 203-210. DOI: 10.1007/s10549-016-3827-7

Translational breast cancer research consortium (TBCRC) 022: A phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases
Freedman, RA, Gelman, RS, Wefel, JS, Melisko, ME, Hess, KR, Connolly, RM, Van Poznak, CH, Niravath, PA, Puhalla, SL, Ibrahim, N, Blackwell, KL, Moy, B, Herold, C, Liu, MC, Lowe, A, Agar, NYR, Ryabin, N, Farooq, S, Lawler, E, Rimawi, MF, Krop, IE, Wolff, AC, Winer, EP & Lin, NU 2016, Journal of Clinical Oncology, vol 34, no. 9, pp. 945-952. DOI: 10.1200/JCO.2015.63.0343

Chemotherapy resistance in breast cancer
Niravath, P & Nangia, J 2015, Current Cancer Therapy Reviews, vol 11, no. 4, pp. 260-268.

The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis
Do, T, Medhekar, R, Bhat, R, Chen, H, Niravath, P & Trivedi, MV 2015, Breast Cancer Research and Treatment, vol 153, no. 3, pp. 591-597. DOI: 10.1007/s10549-015-3531-z

Breast adenocarcinoma recurring as small cell carcinoma in a patient with a germline BRCA2 mutation: Clonal evolution unchecked
Niravath, P, Eble, T, Contreras, A, Li, M, Franco, LM & Rimawi, M 2015, Experimental Hematology and Oncology, vol 4, no. 1, 1. DOI: 10.1186/2162-3619-4-1

A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer
Niravath, P, Tham, YL, Wang, T, Rodriguez, A, Foreman, C, Hilsenbeck, SG, Elledge, R & Rimawi, M 2015, Oncologist, vol 20, no. 1. DOI: 10.1634/theoncologist.2014-0278

Aromatase inhibitor adverse effects: Are we sweeping them under the rug?
Niravath, P, Rimawi, MF & Osborne, CK 2014, Journal of Clinical Oncology, vol 32, no. 33, pp. 3779-3780. DOI: 10.1200/JCO.2014.56.9640

Evaluation of patients for metastasis prior to primary therapy
Niravath, P & Kent Osborne, C 2014, . in Diseases of the Breast: Fifth Edition. Wolters Kluwer Health Adis (ESP).

Aromatase inhibitor-induced arthralgia: A review
Niravath, P 2013, Annals of Oncology, vol 24, no. 6, pp. 1443-1449. DOI: 10.1093/annonc/mdt037

Lactadherin and clearance of platelet-derived microvesicles
Dasgupta, SK, Abdel-Monem, H, Niravath, P, Le, A, Bellera, RV, Langlois, K, Nagata, S, Rumbaut, RE & Thiagarajan, P 2009, Blood, vol 113, no. 6, pp. 1332-1339. DOI: 10.1182/blood-2008-07-167148